Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic/noradrenergic antidepressants during pregnancy: A review

This publication has 111 references indexed in Scilit:

• Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn
  Pharmacoepidemiology and Drug Safety, 2009
• Modulation of Serotonin Transporter Function during Fetal Development Causes Dilated Heart Cardiomyopathy and Lifelong Behavioral Abnormalities
  PLOS ONE, 2008
• Evaluation of the Risk of Congenital Cardiovascular Defects Associated With Use of Paroxetine During Pregnancy
  American Journal of Psychiatry, 2008
• Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population‐based cohort study from the Netherlands
  British Journal of Clinical Pharmacology, 2007
• Prevalence and predictors of antidepressant use in a cohort of pregnant women
  BJOG: An International Journal of Obstetrics & Gynaecology, 2007
• Maternal use of selective serotonin re‐uptake inhibitors in early pregnancy and infant congenital malformations
  Birth Defects Research Part A: Clinical and Molecular Teratology, 2007
• Effects of Selective Serotonin Reuptake Inhibitors and Venlafaxine During Pregnancy in Term and Preterm Neonates
  Pediatrics, 2007
• Maternal Selective Serotonin Reuptake Inhibitor Use During Pregnancy and Newborn Neurobehavior
  Pediatrics, 2004
• Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors
  Acta Paediatrica, 2001
• Congenital anomalies in the newborninfant, including minor variations
  The Journal of Pediatrics, 1964